Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Market Cap	31.95B
Revenue (ttm)	51.13M
Net Income (ttm)	-416.66M
Shares Out	325.98M
EPS (ttm)	-7.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,400
Average Volume	281,287
Open	101.60
Previous Close	101.60
Day's Range	99.00 - 101.90
52-Week Range	56.00 - 103.50
Beta	n/a
RSI	67.38
Earnings Date	n/a

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products includes KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Employees: 348
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2659

Financial Performance

Financial numbers in CNY